Zacks.com on MSN58m
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback